Effect on Beta Cell Function and Glycaemic Control After Insulin and Exenatide Sequential Therapy

• Status: Unknown status
• Trial end date: 2015-09-01
• Target enrollment: 0
• Participant gender: All

Summary

Whether GLP-1 receptor agonists sequential therapy in newly diagnosed type 2 diabetic patients can further improve glycemic control, diabetes remission rate and β-cell function after the short-term insulin intensive therapy.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: xiaolong zhao
• Collaborators: Fuling Central Hospital of Chongqing City; Pudong Gongli hospital of Shanghai; Second Affiliated Hospital of Soochow University; Shanghai Pudong New Area Gongli Hospital; Shanghai Zhongshan Hospital; Taizhou Hospital; The First Hospital of Guiyang Medical college; The third people's Hospital Affiliated to Shanghai Jiao Tong University
• Treatments: Exenatide; Insulin; Insulin, Globin Zinc; Metformin

Criteria

Inclusion Criteria:

• newly diagnosed type 2 diabetes without drug treatment

• 25-70 years old age

• Fasting glucose between 7.0-16.7mmol / L

• BMI at 20 ~ 35 kg/m2 and stable for at least 3 month(weight fluctuations within three months does not exceed 10%)

• females who have no plan of pregnancy during the study

Exclusion Criteria:

• acute or chronic complications of diabetes

• myocardial infarction or cerebrovascular events within three months

• serious gastrointestinal diseases

• other serious concomitant diseases

• liver or kidney dysfunction:Transaminase (ALT and AST) greater than 3 times the upper limit of the normal range or creatinine levels greater than 133μmol / L

• GAD antibodies positive

• history of pancreatitis or pancreatic cancer;

• pregnant or breastfeeding women.

• severe hypertension (blood pressure> 180/110mmhg)

• using corticosteroids, immunosuppressants and cytotoxic therapy.